The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Abstract
Background Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition. We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effects on important secondary outcomes.Methods We searched Medline from Jan 1, 2009, to Nov 19, 2013, limiting searches to phase 3, randomised trials of patients with atrial fibrillation who were randomised to receive new oral anticoagulants or warfarin, and trials in which both efficacy and safety outcomes were reported. We did a prespecified meta-analysis of all 71,683 participants included in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials. The main outcomes were stroke and systemic embolic events, ischaemic stroke, haemorrhagic stroke, all-cause mortality, myocardial infarction, major bleeding, intracranial haemorrhage, and gastrointestinal bleeding. We calculated relative risks (RRs) and 95% CIs for each outcome. We did subgroup analyses to assess whether differences in patient and trial characteristics affected outcomes. We used a random-effects model to compare pooled outcomes and tested for heterogeneity.Findings 42,411 participants received a new oral anticoagulant and 29,272 participants received warfarin. New oral anticoagulants significantly reduced stroke or systemic embolic events by 19% compared with warfarin (RR 0·81, 95% CI 0·73-0·91; p<0·0001), mainly driven by a reduction in haemorrhagic stroke (0·49, 0·38-0·64; p<0·0001). New oral anticoagulants also significantly reduced all-cause mortality (0·90, 0·85-0·95; p=0·0003) and intracranial haemorrhage (0·48, 0·39-0·59; p<0·0001), but increased gastrointestinal bleeding (1·25, 1·01-1·55; p=0·04). We noted no heterogeneity for stroke or systemic embolic events in important subgroups, but there was a greater relative reduction in major bleeding with new oral anticoagulants when the centre-based time in therapeutic range was less than 66% than when it was 66% or more (0·69, 0·59-0·81 vs 0·93, 0·76-1·13; p for interaction 0·022). Low-dose new oral anticoagulant regimens showed similar overall reductions in stroke or systemic embolic events to warfarin (1·03, 0·84-1·27; p=0·74), and a more favourable bleeding profile (0·65, 0·43-1·00; p=0·05), but significantly more ischaemic strokes (1·28, 1·02-1·60; p=0·045).Interpretation This meta-analysis is the first to include data for all four new oral anticoagulants studied in the pivotal phase 3 clinical trials for stroke prevention or systemic embolic events in patients with atrial fibrillation. New oral anticoagulants had a favourable risk-benefit profile, with significant reductions in stroke, intracranial haemorrhage, and mortality, and with similar major bleeding as for warfarin, but increased gastrointestinal bleeding. The relative efficacy and safety of new oral anticoagulants was consistent across a wide range of patients. Our findings offer clinicians a more comprehensive picture of the new oral anticoagulants as a therapeutic option to reduce the risk of stroke in this patient population.Funding None.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oral anticoagulation (OAC) with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) markedly reduces stroke and mortality in AF patients.38,39”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“OAC therapy can prevent the majority of ischaemic strokes in AF patients and can prolong life.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“and hence there is strong evidence that patients with a CHA 2 DS 2 -VASc risk score of 2 or more in men, and 3 or more in women benefit from OAC.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Controlled trials studying OAC in AF patients have been enriched for patients at high risk of stroke, 38,39,42,194,201,329,351,352”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Mortality was 10% lower in patients randomized to NOAC therapy (RR 0.90; 95% CI 0.85-0.95;P = 0.0003) and intracranial haemorrhage was halved (RR 0.48; 95% CI 0.39-0.59;P < 0.0001), while gastrointestinal bleeding events were more frequent (RR 1.25; 95% CI 1.01-1.55;P = 0.04).39”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“NOACs in these dosages significantly reduced stroke or systemic embolic events by 19% compared with warfarin (RR 0.81; 95% CI 0.73-0.91;P < 0.0001), mainly driven by a reduction in haemorrhagic stroke (RR 0.49; 95% CI 0.38-0.64;P < 0.0001).”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“A meta-analysis 39 based on the highdose treatment groups of the pivotal studies of warfarin versus NOACs included 42,411 patients receiving a NOAC and 29,272 receiving warfarin.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Good data are available to support the use of anticoagulants in older patients from BAFTA (Birmingham Atrial Fibrillation Treatment of the Aged Study), 362 the NOAC trials, 39 and from analyses in elderly Americans (Medicare).396”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,924
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · CHEST Journal · doi:10.1378/chest.10-0134 · Cited by 4,517
Cited by
Sorted by citations
Items 601–700 of 1,004
Xian, Y., Zhang, S., Inohara, T., Grau‐Sepulveda, M. V., Matsouaka, R., Peterson, E. D., Piccini, J. P., Smith, E. E., Sheth, K. N., Bhatt, D. L., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.37438 · Cited by 52
Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?
Hanley, C. M., & Kowey, P. R. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2015.01.23 · Cited by 51
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction
Fox, K. A. A., Eikelboom, J. W., Shestakovska, O., Connolly, S. J., Metsarinne, K. P., & Yusuf, S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.048 · Cited by 56
Tsigkas, G., Apostolos, A., Despotopoulos, S., Vasilagkos, G., Kallergis, E. M., Leventopoulos, G., Mplani, V., & Davlouros, P. A. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10133-6 · Cited by 53
Imberti, J. F., Mei, D. A., Vitolo, M., Bonini, N., Proietti, M., Potpara, T., Lip, G. Y. H., & Boriani, G. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.04.023 · Cited by 51
The influence of atrial high-rate episodes on stroke and cardiovascular death: an update
Toennis, T., Bertaglia, E., Brandes, A., Dichtl, W., Fluschnik, N., de Groot, J. R., Marijon, É., Mont, L., Blomström‐Lundqvist, C., Cabanelas, N., et al. (2023) · EP Europace · doi:10.1093/europace/euad166 · Cited by 53
Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III
Connolly, S. J., Healey, J. S., Belley‐Côté, E. P., Balasubramanian, K., Paparella, D., Brady, K., Reents, W., Danner, B. C., Devereaux, P. J., Sharma, M., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.060315 · Cited by 51
Treatment for intracerebral hemorrhage: Dawn of a new era
Seiffge, D. J., & Anderson, C. S. (2024) · International Journal of Stroke · doi:10.1177/17474930241250259 · Cited by 54
Lin, L., Lim, W. S., Zhou, H. J., Khoo, A. L., Tan, K. T., Chew, A. P., Foo, D. C. G., Chin, J. J., & Lim, B. P. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.09.008 · Cited by 52
Dobesh, P. P., & Fanikos, J. R. (2015) · Drugs · doi:10.1007/s40265-015-0452-4 · Cited by 50
Oral Anticoagulant Therapy in Atrial Fibrillation Patients at High Stroke and Bleeding Risk
Potpara, T., & Lip, G. Y. H. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.07.003 · Cited by 52
Evidence for the Prevention and Treatment of Stroke in Dialysis Patients
Herrington, W. G., Haynes, R., Staplin, N., Emberson, J., Baigent, C., & Landray, M. (2014) · Seminars in Dialysis · doi:10.1111/sdi.12281 · Cited by 51
Macha, K., Volbers, B., Bobinger, T., Kurka, N., Breuer, L., Huttner, H. B., Schwab, S., & Köhrmann, M. (2016) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2016.06.031 · Cited by 51
Application of 3D printing technology to left atrial appendage occlusion
Li, H., Qingyao, BingShen, Shu, M., Lizhong, Wang, X., & Song, Z. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.01.031 · Cited by 51
Benz, A. P., Hijazi, Z., Lindbäck, J., Connolly, S. J., Eikelboom, J. W., Oldgren, J., Siegbahn, A. G., & Wallentin, L. C. (2021) · Circulation · doi:10.1161/circulationaha.120.053100 · Cited by 54
Why switch from warfarin to NOACs?
Verdecchia, P., Angeli, F., Aita, A., Bartolini, C., & Reboldi, G. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1411-0 · Cited by 51
Brown, J. D., Shewale, A. R., & Talbert, J. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.9.958 · Cited by 50
Stroke Prevention in the Very Elderly
Lindley, R. I. (2018) · Stroke · doi:10.1161/strokeaha.117.017952 · Cited by 51
Everything the clinician needs to know about evidence-based anticoagulation in pregnancy
Scheres, L. J. J., Bistervels, I. M., & Middeldorp, S. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.08.001 · Cited by 51
Atrial Cardiopathy and Stroke Prevention
Elkind, M. S. V. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1053-0 · Cited by 50
Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation
Kato, E. T., Goto, S., & Giugliano, R. P. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.10.006 · Cited by 51
Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
Alberts, M. J., Chen, Y.-W., Lin, J., Kogan, E., Twyman, K., & Milentijevic, D. (2019) · Stroke · doi:10.1161/strokeaha.119.025554 · Cited by 50
Atrial Fibrillation and Stroke
Essa, H., Hill, A. M., & Lip, G. Y. H. (2021) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2020.11.003 · Cited by 53
Lee, S., Choi, E., Park, S. H., Jung, J., Han, K., Oh, S., & Lip, G. Y. H. (2021) · Stroke · doi:10.1161/strokeaha.120.033338 · Cited by 55
Giugliano, R. P., Ruff, C. T., Rost, N. S., Silverman, S. B., Wiviott, S. D., Lowe, C., Deenadayalu, N., Murphy, S. A., Grip, L. T., Betcher, J., et al. (2014) · Stroke · doi:10.1161/strokeaha.114.006025 · Cited by 49
Lip, G. Y. H., Skjøth, F., Nielsen, P. B., Kjældgaard, J. N., & Larsen, T. B. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1883 · Cited by 50
Cools, F. J. S., Johnson, D., Camm, A. J., Bassand, J., Verheugt, F. W. A., Yang, S., Tsiatis, A. A., Fitzmaurice, D. A., Goldhaber, S. Z., Kayani, G., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15415 · Cited by 51
Sarajlic, P., Simonsson, M., Jernberg, T., Bäck, M., & Hofmann, R. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab059 · Cited by 49
Prediction of short-term atrial fibrillation risk using primary care electronic health records
Nadarajah, R., Wu, J., Hogg, D., Raveendra, K., Nakao, Y. M., Nakao, K., Arbel, R., Haim, M., Zahger, D., Parry, J., et al. (2023) · Heart · doi:10.1136/heartjnl-2022-322076 · Cited by 52
Steinberg, B. A., Simon, D. N., Thomas, L. E., Ansell, J., Fonarow, G. C., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Peterson, E. D., & Piccini, J. P. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.02.015 · Cited by 49
Cangemi, D. J., Krill, T. S., Weideman, R. A., Cipher, D. J., Spechler, S. J., & Feagins, L. A. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.39 · Cited by 49
Nielsen, P. B., Skjøth, F., Søgaard, M., Kjældgaard, J. N., Lip, G. Y. H., & Larsen, T. B. (2019) · Stroke · doi:10.1161/strokeaha.118.023797 · Cited by 49
Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study
Bonde, A. N., Blanche, P., Stærk, L., Gerds, T. A., Gundlund, A., Gislason, G., Torp-Pedersen, C. T., Lip, G. Y. H., Hlatky, M. A., & Olesen, J. B. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz155 · Cited by 49
MRI predicts intracranial hemorrhage in patients who receive long-term oral anticoagulation
Martí‐Fábregas, J., Medrano-Martorell, S., Merino, E., Prats‐Sánchez, L., Marín, R., Delgado‐Mederos, R., Domeño, A. M., Camps‐Renom, P., Jiménez‐Xarrié, E., Zedde, M., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007532 · Cited by 49
Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage in Anticoagulated Patients
Meinel, T. R., Kniepert, J. U., Seiffge, D. J., Gralla, J., Jung, S. C., Auer, E., Frey, S., Goeldlin, M. B., Mordasini, P., Mosimann, P. J., et al. (2020) · Stroke · doi:10.1161/strokeaha.119.026606 · Cited by 49
Wallisch, M., Lorentz, C. U., Lakshmanan, H. H. S., Johnson, J. S., Carris, M. R., Puy, C., Gailani, D., Hinds, M. T., McCarty, O. J. T., Gruber, A., et al. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12309 · Cited by 49
Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease
Srisuwananukorn, A., Raslan, R., Zhang, X., Shah, B. N., Han, J., Gowhari, M., Molokie, R. E., Gordeuk, V. R., & Saraf, S. L. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001384 · Cited by 49
Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation
Sugrue, A. M., Sanborn, D. M., Amin, M., Farwati, M., Sridhar, H., Ahmed, A., Mehta, R. A., Siontis, K. C., Mulpuru, S. K., Deshmukh, A. J., et al. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.062 · Cited by 49
Bahit, M. C., Sacco, R. L., Easton, J. D., Meyerhoff, J., Cronin, L., Kleine, E., Grauer, C., Brueckmann, M., Diener, H.-C., Lópes, R. D., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.055176 · Cited by 48
Komen, J. J., Pottegård, A., Mantel-Teeuwisse, A. K., Forslund, T., Hjemdahl, P., Wettermark, B., Hallas, J., Olesen, M. S., Bennie, M., Mueller, T., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac111 · Cited by 50
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism
Capodanno, D., Alexander, J. H., Bahit, M. C., Eikelboom, J. W., Gibson, C. M., Goodman, S. G., Kunadian, V., Lip, G. Y. H., Lópes, R. D., Mehran, R., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01144-z · Cited by 57
Loffredo, L., Perri, L., & Violi, F. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.01.159 · Cited by 48
High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme
Sandhu, R. K., Dolovich, L. R., Deif, B., Barake, W. M., Agarwal, G., Grinvalds, A., Lim, T., Quinn, F. R., Gladstone, D. J., Conen, D., et al. (2016) · Open Heart · doi:10.1136/openhrt-2016-000515 · Cited by 48
Milling, T. J., & Frontera, J. A. (2017) · PubMed · Cited by 48
Zeballos-Palacios, C. L., Hargraves, I. G., Noseworthy, P. A., Branda, M. E., Kunneman, M., Burnett, B., Gionfriddo, M. R., McLeod, C. J., Gorr, H. S., Brito, J. P., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.030 · Cited by 48
Lee, H., Kim, H., Jung, J., Han, K., Lee, H., Park, J., Kim, H. M., Kim, Y.-J., & Ommen, S. R. (2019) · Stroke · doi:10.1161/strokeaha.119.026048 · Cited by 48
Anticoagulation strategies in extracorporeal circulatory devices in adult populations
Kato, C. M., Oakes, M., Kim, M., Desai, A., Olson, S. R., Raghunathan, V. M., & Shatzel, J. J. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13520 · Cited by 48
Lombardi, F., Paoletti, L., Carrieri, B., Dell’Aquila, G., Fedecostante, M., Muzio, M. D., Corsonello, A., Lattanzio, F., & Cherubini, A. (2021) · European Geriatric Medicine · doi:10.1007/s41999-021-00471-x · Cited by 50
Metzner, A., Suling, A. I., Brandes, A., BREITHARDT, G. E., Camm, A. J., Crijns, H. J. G. M., Eckardt, L., Elvan, A., Goette, A., Haegeli, L., et al. (2021) · EP Europace · doi:10.1093/europace/euab200 · Cited by 47
Grottke, O., Afshari, A., Ahmed, A. B., Arnaoutoglou, E. M., Bolliger, D., Eriksen, C. F., & von Heymann, C. (2024) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000001968 · Cited by 47
Jain, S. S., Mahaffey, K. W., Pieper, K. S., Shimizu, W., Potpara, T., Ruff, C. T., Kamel, H., Lewis, B. S., Cornel, J. H., Kowey, P. R., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.08.011 · Cited by 51
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 58
He, Y., Wong, I. C. K., Li, X., Anand, S., Leung, W. K., Siu, C., & Chan, E. W. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12911 · Cited by 47
Fanola, C. L., Giugliano, R. P., Ruff, C. T., Trevisan, M., Nordio, F., Mercuri, M. F., Antman, E. M., & D, E. B. M. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw565 · Cited by 47
Hellwig, S., Grittner, U., Audebert, H. J., Endres, M., & Hæusler, K. G. (2017) · EP Europace · doi:10.1093/europace/eux087 · Cited by 47
Green, L., Tan, J., Morris, J. K., Alikhan, R., Curry, N. S., Everington, T., Maclean, R., Saja, K., Stanworth, S. J., Tait, R. C., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.182220 · Cited by 47
Cipriano, A., Pecori, A., Bionda, A. E., Bardini, M., Frassi, F., Leoli, F., Lami, V., Ghiadoni, L., & Santini, M. (2018) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1806-1 · Cited by 47
Leow, A. S., Sia, C., Tan, B. Y., & Loh, J. P.-Y. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1656-8 · Cited by 47
Gastrointestinal Bleeding With Edoxaban Versus Warfarin
Aisenberg, J., Chatterjee-Murphy, P., Flack, K. F., Weitz, J. I., Ruff, C. T., Nordio, F., Mercuri, M. F., Choi, Y., Antman, E. M., Braunwald, E., et al. (2018) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.117.003998 · Cited by 47
Shimada, K., Hasegawa, S., Nakao, S., Mukai, R., Sasaoka, S., Ueda, N., Kato, Y., Abe, J., Mōri, T., Yoshimura, T., et al. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.34629 · Cited by 47
Lévy, S., Steinbeck, G., Santini, L., Näbauer, M., Penela, D., Kantharia, B. K., Saksena, S. V., & Cappato, R. (2022) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-022-01195-z · Cited by 50
The Aging Heart: A Molecular and Clinical Challenge
Lazzeroni, D., Villatore, A., Souryal, G., Pili, G., & Peretto, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416033 · Cited by 52
2020 Clinical practice guidelines for Hypertrophic cardiomyopathy
Габрусенко, С. А., Gudkova, A. Y., Koziolova, N. A., Alexandrova, S. А., Berseneva, M., Гордеев, М. Л., Sl, D., Zaklyazminskaya, E. V., Irtyuga, O. B., Kaplunova, V. Y., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4541 · Cited by 56
Dehbi, H., Fischer, U., Åsberg, S., Milling, T. J., Abend, S., Ahmed, N., Branca, M., Davis, L. A., Engelter, S. T., Freemantle, N., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00439-8 · Cited by 46
Ito, M., Kaikita, K., Sueta, D., Ishii, M., Oimatsu, Y., Arima, Y., Iwashita, S., Takahashi, A., Hoshiyama, T., Kanazawa, H., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002744 · Cited by 46
Interventional and surgical occlusion of the left atrial appendage
Caliskan, E., Cox, J. L., Holmes, D. R., Meier, B., Lakkireddy, D., Falk, V., Salzberg, S. P., & Emmert, M. Y. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.107 · Cited by 45
Atrial fibrillation in the Middle East: unmapped, underdiagnosed, undertreated
Al-Shamkhani, W., Ayetey, H., & Lip, G. Y. H. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1457953 · Cited by 46
Becattini, C., Giustozzi, M., Ranalli, M. G., Bogliari, G., Cianella, F., Verso, M., Agnelli, G., & Vedovati, M. C. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13985 · Cited by 46
Sengupta, N., Marshall, A. L., Jones, B. A., Ham, S. A., & Tapper, E. B. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.05.005 · Cited by 48
Reddy, V. Y., Akehurst, R. L., Gavaghan, M. B., Amorosi, S. L., & Holmes, D. R. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011577 · Cited by 46
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial
Bergmark, B. A., Kamphuisen, P. W., Wiviott, S. D., Ruff, C. T., Antman, E. M., Nordio, F., Kuder, J., Mercuri, M. F., Lanz, H., Braunwald, E., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041346 · Cited by 47
Rasmussen, P. V., Dalgaard, F., Gislason, G., Brandes, A., Johnsen, S. P., Grove, E. L., Torp-Pedersen, C. T., Dybro, L., Harboe, L., Münster, A. B., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz964 · Cited by 46
Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention
Khan, S. U., Osman, M., Khan, M. U., Khan, M. S., Zhao, D., Mamas, M. A., Savji, N., Al‐Abdouh, A., Hasan, R. K., & Michos, E. D. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3763 · Cited by 49
Kohsaka, S., Katada, J., Saito, K., Jenkins, A. K., Li, B. H., Mardekian, J., & Terayama, Y. (2020) · Open Heart · doi:10.1136/openhrt-2019-001232 · Cited by 46
Coleman, C. I., Dobesh, P. P., Danese, S. R., Ulloa, J., & Lovelace, B. (2020) · Future Cardiology · doi:10.2217/fca-2020-0073 · Cited by 46
Paschke, L. M., Klimke, K., Altiner, A., von Stillfried, D., & Schulz, M. (2020) · BMC Medicine · doi:10.1186/s12916-020-01695-7 · Cited by 50
Hanon, O., Vidal, J., Pisica–Donose, G., Orvoën, G., David, J., Chaussade, E., Caillard, L. K., de Jong, L. W., Boulloche, N., Vinsonneau, U., et al. (2020) · Heart · doi:10.1136/heartjnl-2020-317923 · Cited by 47
Alzheimer’s disease: the impact of age-related changes in reproductive hormones
Bates, K., Harvey, A. R., Carruthers, M., & Martins, R. N. (2005) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-004-4383-1 · Cited by 47
Maegele, M. (2021) · Neurosurgery · doi:10.1093/neuros/nyab358 · Cited by 45
Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke
Seiffge, D. J., Traenka, C., Polymeris, A. A., Hert, L., Fisch, U., Peters, N., Marchis, G. M. D., Guzman, R. G., Nickel, C. H., Lyrer, P., et al. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1431-7 · Cited by 45
Pannach, S., Goetze, J., Marten, S., Schreier, T., Tittl, L., & Beyer‐Westendorf, J. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1320-7 · Cited by 45
Mechanisms And Management Of Thrombo-Embolism In Atrial Fibrillation.
Violi, F., Pastori, D., & Pignatelli, P. (2014) · Europe PMC (PubMed Central) · doi:10.4022/jafib.1112 · Cited by 45
Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy
Foerster, K. I., Huppertz, A., Müller, O. J., Rizos, T., Tilemann, L. M., Haefeli, W. E., & Burhenne, J. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.10.011 · Cited by 45
Altiok, E., & Marx, N. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0776 · Cited by 47
Cavallari, I., Verolino, G., Romano, S., & Patti, G. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-3400300 · Cited by 45
Savioli, G., Ceresa, I. F., Luzzi, S., Gragnaniello, C., Lucifero, A. G., Maestro, M. D., Marasco, S., Manzoni, F., Ciceri, L., Gelfi, E., et al. (2020) · Medicina · doi:10.3390/medicina56060308 · Cited by 45
Tanawuttiwat, T., Stebbins, A., Marquis‐Gravel, G., Vemulapalli, S., Kosinski, A. S., & Cheng, A. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.023561 · Cited by 45
Cavallari, I., & Patti, G. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.12.014 · Cited by 45
Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants
Benamouzig, R., Guenoun, M., Deutsch, D., & Fauchier, L. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07211-0 · Cited by 49
Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation
Wu, J., Nadarajah, R., Nakao, Y. M., Nakao, K., Wilkinson, C., Cowan, J. C., Camm, A. J., & Gale, C. P. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad571 · Cited by 47
Fu, W., Guo, H., Guo, J., Lin, K., Wang, H., Zhang, Y., Wang, Y., & Shan, Z. (2014) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000206 · Cited by 44
Appelmann, I., Kreher, S., Parmentier, S. B., Wolf, H., Bisping, G., Kirschner, M., Bergmann, F., Schilling, K., Brümmendorf, T. H., Petrides, P. E., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2621-2 · Cited by 45
Russo, V., Rago, A., Proietti, R., Meo, F. D., Papa, A. A., Calabrò, P., D’Onofrio, A., Nigro, G., & AlTurki, A. (2016) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098616673990 · Cited by 44
Direct Oral Anticoagulants in Emergency Trauma Admissions
Maegele, M., Grottke, O., Schöchl, H., Sakowitz, O. W., Spannagl, M., & Koscielny, J. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0575 · Cited by 45
Thorp, B. C., & Badoux, X. C. A. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1339874 · Cited by 44
Shared Decision-Making as the Future of Emergency Cardiology
Probst, M. A., Noseworthy, P. A., Brito, J. P., & Hess, E. P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.09.014 · Cited by 44
Rago, A., Papa, A. A., Meo, F. D., Attena, E., Golino, P., D’Onofrio, A., Nigro, G., & Russo, V. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1607436 · Cited by 44
Chao, T., Chiang, C., Liao, J., Chen, T., Lip, G. Y. H., & Chen, S. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.11.025 · Cited by 44
Radadiya, D. K., Devani, K., Brahmbhatt, B. S., & Reddy, C. M. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002035 · Cited by 50
Metadata
- Authors
- Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., Yamashita, T., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Thomas Jefferson University (US)
- St George's, University of London (GB)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Carmel Medical Center (IL)
- Cardiovascular Institute Hospital (JP)
- Corresponding author
- Ruff, Christian T
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 383
- Issue
- 9921
- Pages
- 955-962
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2152623033
- Cited by
- 5,051
- References
- 45
- Citations by year
- 2026: 249 · 2025: 310 · 2024: 399 · 2023: 426 · 2022: 410 · 2021: 490 · 2020: 521 · 2019: 462 · 2018: 456 · 2017: 447 · 2016: 406 · 2015: 318 · 2014: 139
- FWCI
- 49.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- direct oral anticoagulants, warfarin, atrial fibrillation, stroke prevention, systemic embolism, hemorrhagic stroke, intracranial hemorrhage, gastrointestinal bleeding, major bleeding, all-cause mortality, subgroup analysis, factor Xa inhibitors, dabigatran, rivaroxaban, apixaban
- MeSH terms
- Administration, Oral, Anticoagulants, Atrial Fibrillation, Embolism, Humans, Warfarin, Randomized Controlled Trials as Topic, Treatment Outcome, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
